WuXi AppTec forecasts 70% revenue growth
WuXi AppTec (2359) announced that it has resumed regular business operations in Shanghai, adding that it remains confident that its full-year revenue will increase 65-70% this year compared to a year ago. .
The medical technology company reiterated that its second quarter revenue will grow 63-65% from a year earlier.
This came as CanSino Biologics (6185) ended its collaboration with Pfizer on promoting a meningococcal conjugate vaccine.
CanSino said it signed a cooperation agreement with Pfizer in July 2020, under which the Chinese vaccine developer allowed Pfizer to exclusively promote the company’s vaccine, Manhaixin, in mainland China for a period of cooperation of up to 10 days. year.
It ended cooperation with Pfizer on June 4 this year after friendly negotiations, it said in a regulatory filing on the Hong Kong stock exchange yesterday.
CanSino’s own marketing team will help the company formulate and execute promotion strategies and domestic and international marketing operations for the product, he added.
Separately, Clover Biopharmaceuticals (2197) said it plans to submit an application for its Covid vaccine candidate in the second half of the year.